Modified vaccinia virus ankara-based vaccine vectors induce apoptosis in dendritic cells draining from the skin via both the extrinsic and intrinsic caspase pathways, preventing efficient antigen presentation

Journal of Virology

Volumn 86, Issue 10, 2012, Pages 5452-5466

  Guzman, E ^a   Cubillos Zapata, C ^a   Cottingham, M G ^b   Gilbert, S C ^b   Prentice, H ^a   Charleston, B ^a   Hope, J C ^a,c  

^a INSTITUTE FOR ANIMAL HEALTH   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; ADENOVIRUS VECTOR; B7 ANTIGEN; CASPASE 8; CASPASE 9; CD4 ANTIGEN; CD40 ANTIGEN; CD8 ANTIGEN; CD86 ANTIGEN; COMPLEMENT COMPONENT C3D RECEPTOR; DEC 205 ANTIGEN; GAMMA INTERFERON; GLYCOPROTEIN P 15095; LYMPHOCYTE ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MODIFIED VACCINIA VIRUS ANKARA VECTOR; MYCOBACTERIUM ANTIGEN; MYCOBACTERIUM ANTIGEN 85A; PROTEIN SIRP ALPHA; REGULATOR PROTEIN; UNCLASSIFIED DRUG; VIRUS VECTOR;

AFFERENT LYMPHATIC DENDRITIC CELL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN PRESENTATION; APOPTOSIS; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DEATH; CELL PHAGOCYTOSIS; CONTROLLED STUDY; DENDRITIC CELL; DOWN REGULATION; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE EXPRESSION REGULATION; HUMAN ADENOVIRUS 5; IN VITRO STUDY; INTERFERON PRODUCTION; LYMPHOCYTE MIGRATION; NONHUMAN; PRIORITY JOURNAL; SKIN; VACCINIA VIRUS; VIRAL GENE DELIVERY SYSTEM; VIRUS ATTACHMENT; VIRUS ENTRY; VIRUS GENE; VIRUS RECOMBINANT;

ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, BACTERIAL; APOPTOSIS; CASPASES; CATTLE; DENDRITIC CELLS; DOWN-REGULATION; GENETIC VECTORS; HUMANS; MYCOBACTERIUM BOVIS; SIGNAL TRANSDUCTION; TUBERCULOSIS; VACCINIA VIRUS; VIRAL VACCINES;

BOVINAE; HUMAN ADENOVIRUS TYPE 5; VACCINIA VIRUS ANKARA;

EID: 84861325093     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00264-12     Document Type: Article

References (83)

1. Antonis AF, et al. 2007. Vaccination with recombinant modified vaccinia virus Ankara expressing bovine respiratory syncytial virus (bRSV) proteins protects calves against RSV challenge. Vaccine 25:4818-4827.
2. Behboudi S, Moore A, Gilbert SC, Nicoll CL, Hill AV. 2004. Dendritic cells infected by recombinant modified vaccinia virus Ankara retain immunogenicity in vivo despite in vitro dysfunction. Vaccine 22:4326-4331.
3. Betts MR, et al. 2005. Characterization of functional and phenotypic changes in anti-Gag vaccine-induced T cell responses and their role in protection after HIV-1 infection. Proc. Natl. Acad. Sci. U. S. A. 102:4512- 4517.
4. Brandler S, et al. 2010. Preclinical studies of a modified vaccinia virus Ankara-based HIV candidate vaccine: antigen presentation and antiviral effect. J. Virol. 84:5314 -5328.
5. Brooke GP, Parsons KR, Howard CJ. 1998. Cloning of two members of the SIRP alpha family of protein tyrosine phosphatase binding proteins in cattle that are expressed on monocytes and a subpopulation of dendritic cells and which mediate binding to CD4 T cells. Eur. J. Immunol. 28:1-11.
6. Butcher EC, Picker LJ. 1996. Lymphocyte homing and homeostasis. Science 272:60-66.
7. Carroll MW, et al. 1997. Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model. Vaccine 15:387-394.
8. Carson C, et al. 2009. A prime/boost DNA/modified vaccinia virus Ankara vaccine expressing recombinant Leishmania DNA encoding TRYP is safe and immunogenic in outbred dogs, the reservoir of zoonotic visceral leishmaniasis. Vaccine 27:1080 -1086.
9. Casimiro DR, et al. 2003. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replicationdefective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J. Virol. 77:6305- 6313.
10. Cebere I, et al. 2006. Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers. Vaccine 24:417- 425.
11. Chahroudi A, et al. 2006. Differences and similarities in viral life cycle progression and host cell physiology after infection of human dendritic cells with modified vaccinia virus Ankara and vaccinia virus. J. Virol. 80: 8469-8481.
12. Cheong C, et al. 2010. Improved cellular and humoral immune responses in vivo following targeting of HIV Gag to dendritic cells within human anti-human DEC205 monoclonal antibody. Blood 116:3828 -3838.
13. Colditz GA, et al. 1994. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 271:698- 702.
14. Contreras V, et al. 2010. Existence of CD8alpha-like dendritic cells with a conserved functional specialization and a common molecular signature in distant mammalian species. J. Immunol. 185:3313-3325.
15. Coulibaly S, et al. 2005. The nonreplicating smallpox candidate vaccines defective vaccinia Lister (dVV-L) and modified vaccinia Ankara (MVA) elicit robust long-term protection. Virology 341:91-101.
16. Crozat K, et al. 2010. The XC chemokine receptor 1 is a conserved selective marker of mammalian cells homologous to mouse CD8alpha_ dendritic cells. J. Exp. Med. 207:1283-1292.
17. Cubillos-Zapata C, et al. 2011. Differential effects of viral vectors on migratory afferent lymph dendritic cells in vitro predict enhanced immunogenicity in vivo. J. Virol. 85:9385-9394.
18. Dobbelstein M, Shenk T. 1996. Protection against apoptosis by the vaccinia virus SPI-2 (B13R) gene product. J. Virol. 70:6479-6485.
19. Dorrell L, et al. 2006. Expansion and diversification of virus-specific T cells following immunization of human immunodeficiency virus type 1 (HIV-1)-infected individuals with a recombinant modified vaccinia virus Ankara/HIV-1 Gag vaccine. J. Virol. 80:4705- 4716.
20. Drexler I, Heller K, Wahren B, Erfle V, Sutter G. 1998. Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells. J. Gen. Virol. 79(Pt 2):347-352.
21. Drillien R, Spehner D, Hanau D. 2004. Modified vaccinia virus Ankara induces moderate activation of human dendritic cells. J. Gen. Virol. 85: 2167-2175.
22. Eitz Ferrer P, et al. 2011. Induction of Noxa-mediated apoptosis by modified vaccinia virus Ankara depends on viral recognition by cytosolic helicases, leading to IRF-3/IFN-beta-dependent induction of proapoptotic Noxa. PLoS Pathog. 7:e1002083.
23. Ferrer MF, et al. 2011. Recombinant MVA expressing secreted glycoprotein D of BoHV-1 induces systemic and mucosal immunity in animal models. Viral Immunol. 24:331-339.
24. Flechsig C, et al. 2011. Uptake of antigens from modified vaccinia Ankara virus-infected leukocytes enhances the immunostimulatory capacity of dendritic cells. Cytotherapy 13:739 -752.
25. Garcia-Arriaza J, et al. 2011. A candidate HIV/AIDS vaccine (MVA-B) lacking vaccinia virus gene C6L enhances memory HIV-1-specific T-cell responses. PLoS One 6:e24244.
26. Gasteiger G, Kastenmuller W, Ljapoci R, Sutter G, Drexler I. 2007. Cross-priming of cytotoxic T cells dictates antigen requisites for modified vaccinia virus Ankara vector vaccines. J. Virol. 81:11925-11936.
27. Geiben-Lynn R, Greenland JR, Frimpong-Boateng K, Letvin NL. 2008. Kinetics of recombinant adenovirus type 5, vaccinia virus, modified vaccinia ankara virus, and DNA antigen expression in vivo and the induction of memory T-lymphocyte responses. Clin. Vaccine Immunol. 15:691- 696.
28. Gliddon DR, Hope JC, Brooke GP, Howard CJ. 2004. DEC-205 expression on migrating dendritic cells in afferent lymph. Immunology 111:262- 272.
29. Gliddon DR, Howard CJ. 2002. CD26 is expressed on a restricted subpopulation of dendritic cells in vivo. Eur. J. Immunol. 32:1472-1481.
30. Gubser C, et al. 2007. A new inhibitor of apoptosis from vaccinia virus and eukaryotes. PLoS Pathog. 3:e17.
31. Guilliams M, et al. 2010. From skin dendritic cells to a simplified classification of human and mouse dendritic cell subsets. Eur. J. Immunol. 40:2089 -2094.
32. Hemati B, et al. 2009. Bluetongue virus targets conventional dendritic cells in skin lymph. J. Virol. 83:8789-8799.
33. Hope JC, et al. 2012. Migratory sub-populations of afferent lymphatic dendritic cells differ in their interactions with Mycobacterium bovis Bacille Calmette Guerin. Vaccine 30:2357-2367.
34. Hope JC, Howard CJ, Prentice H, Charleston B. 2006. Isolation and purification of afferent lymph dendritic cells that drain the skin of cattle. Nat. Protoc. 1:982-987.
35. Hope JC, et al. 2002. Development of detection methods for ruminant interleukin (IL)-12. J. Immunol. Methods 266:117-126.
36. Hope JC, et al. 2005. Exposure to Mycobacterium avium induces lowlevel protection from Mycobacterium bovis infection but compromises diagnosis of disease in cattle. Clin. Exp. Immunol. 141:432- 439.
37. Hope JC, et al. 2005. Vaccination of neonatal calves with Mycobacterium bovis BCG induces protection against intranasal challenge with virulent M. bovis. Clin. Exp. Immunol. 139:48 -56.
38. Howard CJ, et al. 1991. Summary of workshop findings for leukocyte antigens of cattle. Vet. Immunol. Immunopathol. 27:21-27.
39. Howard CJ, Naessens J. 1993. Summary of workshop findings for cattle (tables 1 and 2). Vet. Immunol. Immunopathol. 39:25- 47.
40. Howard CJ, et al. 1997. Identification of two distinct populations of dendritic cells in afferent lymph that vary in their ability to stimulate T cells. J. Immunol. 159:5372-5382.
41. Humrich JY, et al. 2007. Vaccinia virus impairs directional migration and chemokine receptor switch of human dendritic cells. Eur. J. Immunol. 37:954 -965.
42. Kalbacova M, Spisakova M, Liskova J, Melkova Z. 2008. Lytic infection with vaccinia virus activates caspases in a Bcl-2-inhibitable manner. Virus Res. 135:53- 63.
43. Kastenmuller W, et al. 2006. Infection of human dendritic cells with recombinant vaccinia virus MVA reveals general persistence of viral early transcription but distinct maturation-dependent cytopathogenicity. Virology 350:276 -288.
44. Kreijtz JH, et al. 2009. Preclinical evaluation of a modified vaccinia virus Ankara (MVA)-based vaccine against influenza A/H5N1 viruses. Vaccine 27:6296-6299.
45. Kreijtz JH, et al. 2009. Recombinant modified vaccinia virus Ankara expressing the hemagglutinin gene confers protection against homologous and heterologous H5N1 influenza virus infections in macaques. J. Infect. Dis. 199:405- 413.
46. Larsson M, et al. 2001. Efficiency of cross presentation of vaccinia virusderived antigens by human dendritic cells. Eur. J. Immunol. 31:3432- 3442.
47. Liu L, Chavan R, Feinberg MB. 2008. Dendritic cells are preferentially targeted among hematolymphocytes by modified vaccinia virus Ankara and play a key role in the induction of virus-specific T cell responses in vivo. BMC Immunol. 9:15.
48. Liu Y, et al. 2006. Hierarchy of alpha fetoprotein (AFP)-specific T cell responses in subjects with AFP-positive hepatocellular cancer. J. Immunol. 177:712-721.
49. Marquet F, et al. 2011. Characterization of dendritic cells subpopulations in skin and afferent lymph in the swine model. PLoS One 6:e16320.
50. Mayr A, Stickl H, Muller HK, Danner K, Singer H. 1978. The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism. Zentralbl. Bakteriol. B 167:375-390. (In German.)
51. McKeever DJ, Awino E, Morrison WI. 1992. Afferent lymph veiled cells prime CD4_ T cell responses in vivo. Eur. J. Immunol. 22:3057-3061.
52. McKeever DJ, MacHugh ND, Goddeeris BM, Awino E, Morrison WI. 1991. Bovine afferent lymph veiled cells differ from blood monocytes in phenotype and accessory function. J. Immunol. 147:3703-3709.
53. McShane H, Behboudi S, Goonetilleke N, Brookes R, Hill AV. 2002. Protective immunity against Mycobacterium tuberculosis induced by dendritic cells pulsed with both CD8(_)- and CD4(_)-T-cell epitopes from antigen 85A. Infect. Immun. 70:1623-1626.
54. McShane H, et al. 2004. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat. Med. 10:1240 -1244.
55. Meyer RG, et al. 2005. A phase I vaccination study with tyrosinase in patients with stage II melanoma using recombinant modified vaccinia virus Ankara (MVA-hTyr). Cancer Immunol. Immunother. 54:453- 467.
56. Moorthy VS, et al. 2003. Safety and immunogenicity of DNA/modified vaccinia virus Ankara malaria vaccination in African adults. J. Infect. Dis. 188:1239 -1244.
57. Norbury CC, et al. 2004. CD8_ T cell cross-priming via transfer of proteasome substrates. Science 304:1318 -1321.
58. Norder M, et al. 2010. Modified vaccinia virus Ankara exerts potent immune modulatory activities in a murine model. PLoS One 5:e11400.
59. Ondondo BO, et al. 2006. Immunisation with recombinant modified vaccinia virus Ankara expressing HIV-1 gag in HIV-1-infected subjects stimulates broad functional CD4_ T cell responses. Eur. J. Immunol. 36:2585-2594.
60. Palucka K, Banchereau J, Mellman I. 2010. Designing vaccines based on biology of human dendritic cell subsets. Immunity 33:464-478.
61. Pillai VK, et al. 2011. Different patterns of expansion, contraction and memory differentiation of HIV-1 Gag-specific CD8 T cells elicited by adenovirus type 5 and modified vaccinia Ankara vaccines. Vaccine 29: 5399-5406.
62. Reyes-Sandoval A, et al. 2010. Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8_ T-cell responses. Infect. Immun. 78:145-153.
63. Rossi M, Young JW. 2005. Human dendritic cells: potent antigenpresenting cells at the crossroads of innate and adaptive immunity. J. Immunol. 175:1373-1381.
64. Rothberg KG, et al. 1992. Caveolin, a protein component of caveolae membrane coats. Cell 68:673- 682.
65. Sakr SW, et al. 2001. The uptake and degradation of matrix-bound lipoproteins by macrophages require an intact actin cytoskeleton, Rho family GTPases, and myosin ATPase activity. J. Biol. Chem. 276:37649 -37658.
66. Sallusto F, Cella M, Danieli C, Lanzavecchia A. 1995. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J. Exp. Med. 182: 389-400.
67. Schafer B, et al. 2011. Pre-clinical efficacy and safety of experimental vaccines based on non-replicating vaccinia vectors against yellow fever. PLoS One 6:e24505.
68. Schwartz-Cornil I, Epardaud M, Bonneau M. 2006. Cervical duct cannulation in sheep for collection of afferent lymph dendritic cells from head tissues. Nat. Protoc. 1:874-879.
69. Serna A, Ramirez MC, Soukhanova A, Sigal LJ. 2003. Cutting edge: efficient MHC class I cross-presentation during early vaccinia infection requires the transfer of proteasomal intermediates between antigen donor and presenting cells. J. Immunol. 171:5668 -5672.
70. Shen X, Wong SB, Buck CB, Zhang J, Siliciano RF. 2002. Direct priming and cross-priming contribute differentially to the induction of CD8_ CTL following exposure to vaccinia virus via different routes. J. Immunol. 169:4222- 4229.
71. Steinman RM. 1991. The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol. 9:271-296.
72. Stephens SA, Brownlie J, Charleston B, Howard CJ. 2003. Differences in cytokine synthesis by the sub-populations of dendritic cells from afferent lymph. Immunology 110:48 -57.
73. Streilein JW, Grammer SF, Yoshikawa T, Demidem A, Vermeer M. 1990. Functional dichotomy between Langerhans cells that present antigen to naive and to memory/effector T lymphocytes. Immunol. Rev. 117: 159-183.
74. Tsung K, Yim JH, Marti W, Buller RM, Norton JA. 1996. Gene expression and cytopathic effect of vaccinia virus inactivated by psoralen and long-wave UV light. J. Virol. 70:165-171.
75. Vieth JA, Kim MK, Pan XQ, Schreiber AD, Worth RG. 2010. Differential requirement of lipid rafts for FcgammaRIIA mediated effector activities. Cell. Immunol. 265:111-119.
76. Vordermeier HM, et al. 2004. Cellular immune responses induced in cattle by heterologous prime-boost vaccination using recombinant viruses and Bacille Calmette-Guerin. Immunology 112:461- 470.
77. Vordermeier HM, et al. 2009. Viral booster vaccines improve Mycobacterium bovis BCG-induced protection against bovine tuberculosis. Infect. Immun. 77:3364 -3373.
78. Wang LH, Rothberg KG, Anderson RG. 1993. Mis-assembly of clathrin lattices on endosomes reveals a regulatory switch for coated pit formation. J. Cell Biol. 123:1107-1117.
79. West MA, Bretscher MS, Watts C. 1989. Distinct endocytotic pathways in epidermal growth factor-stimulated human carcinoma A431 cells. J. Cell Biol. 109:2731-2739.
80. Whelan AO, et al. 2003. Modulation of the bovine delayed-type hypersensitivity responses to defined mycobacterial antigens by a synthetic bacterial lipopeptide. Infect. Immun. 71:6420-6425.
81. Yrlid U, Macpherson G. 2003. Phenotype and function of rat dendritic cell subsets. APMIS 111:756 -765.
82. Yu E, et al. 2011. Structural determinants of caspase-9 inhibition by the vaccinia virus protein, F1L. J. Biol. Chem. 286:30748 -30758.
83. Zhu X, Venkataprasad N, Ivanyi J, Vordermeier HM. 1997. Vaccination with recombinant vaccinia viruses protects mice against Mycobacterium tuberculosis infection. Immunology 92:6 -9.